# Sivik Global Healthcare LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1596452. Source: https://holderbook.com/funds/1596452-sivik-global-healthcare-llc/

- Reported value: $131.7M
- Positions: 34
- Weight of the ten largest: 46.6%
- Filed: 2026-07-20

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| SPDR SERIES TRUST | [XBI](https://holderbook.com/stocks/XBI/) | $19.2M | 150,000 | 14.5% | 8 |
| CARDINAL HEALTH INC | [CAH](https://holderbook.com/stocks/CAH/) | $5.1M | 24,000 | 3.9% | 19 |
| CALL- BSX 100 @ 75  EXP 04/17/2026 | - | $5.0M | 800 | 3.8% | 2 |
| JOHNSON & JOHNSON | [JNJ](https://holderbook.com/stocks/JNJ/) | $4.9M | 20,000 | 3.7% | 2 |
| MERCK & CO INC | [MRK](https://holderbook.com/stocks/MRK/) | $4.8M | 40,000 | 3.7% | 3 |
| CENCORA INC | [COR](https://holderbook.com/stocks/COR/) | $4.7M | 15,000 | 3.6% | 9 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $4.6M | 5,000 | 3.5% | 21 |
| WATERS CORP | [WAT](https://holderbook.com/stocks/WAT/) | $4.5M | 15,000 | 3.4% | 2 |
| VERTEX PHARMACEUTICALS INC | [VRTX](https://holderbook.com/stocks/VRTX/) | $4.5M | 10,000 | 3.4% | 4 |
| INTUITIVE SURGICAL INC | [ISRG](https://holderbook.com/stocks/ISRG/) | $4.1M | 9,000 | 3.2% | 19 |
| ASTRAZENECA PLC | [AZN](https://holderbook.com/stocks/AZN/) | $3.9M | 20,000 | 3.0% | 2 |
| THERMO FISHER SCIENTIFIC INC | [TMO](https://holderbook.com/stocks/TMO/) | $3.9M | 8,000 | 3.0% | 4 |
| BOSTON SCIENTIFIC CORP | [BSX](https://holderbook.com/stocks/BSX/) | $3.9M | 62,000 | 3.0% | 24 |
| DANAHER CORP DEL | [DHR](https://holderbook.com/stocks/DHR/) | $3.8M | 20,000 | 2.9% | 31 |
| TENET HEALTHCARE CORP | [THC](https://holderbook.com/stocks/THC/) | $3.8M | 20,000 | 2.9% | 23 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $3.5M | 25,000 | 2.6% | 3 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $3.5M | 20,000 | 2.6% | 31 |
| METTLER TOLEDO INTERNATIONAL | [MTD](https://holderbook.com/stocks/MTD/) | $3.5M | 2,750 | 2.6% | 3 |
| MCKESSON CORP | [MCK](https://holderbook.com/stocks/MCK/) | $3.5M | 4,000 | 2.6% | 26 |
| AGILENT TECHNOLOGIES INC | [A](https://holderbook.com/stocks/A/) | $3.4M | 30,000 | 2.6% | 7 |
| STRYKER CORPORATION | [SYK](https://holderbook.com/stocks/SYK/) | $3.3M | 10,000 | 2.5% | 31 |
| ABBVIE INC | [ABBV](https://holderbook.com/stocks/ABBV/) | $3.3M | 15,000 | 2.5% | 4 |
| UNIVERSAL HLTH SVCS INC | [UHS](https://holderbook.com/stocks/UHS/) | $3.1M | 17,500 | 2.4% | 24 |
| REGENERON PHARMACEUTICALS | [REGN](https://holderbook.com/stocks/REGN/) | $3.1M | 4,000 | 2.3% | 2 |
| BIO RAD LABS INC | [BIO](https://holderbook.com/stocks/BIO/) | $2.8M | 10,000 | 2.1% | 5 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $2.8M | 15,000 | 2.1% | 3 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $2.7M | 10,000 | 2.1% | 7 |
| GLOBUS MED INC | [GMED](https://holderbook.com/stocks/GMED/) | $2.6M | 30,000 | 2.0% | 3 |
| ABBOTT LABORATORIES | [ABT](https://holderbook.com/stocks/ABT/) | $2.6M | 25,000 | 1.9% | 8 |
| EDWARDS LIFESCIENCES CORP | [EW](https://holderbook.com/stocks/EW/) | $1.6M | 20,000 | 1.2% | 3 |
| SMITH & NEPHEW PLC | [SNN](https://holderbook.com/stocks/SNN/) | $1.6M | 50,000 | 1.2% | 11 |
| ELEVANCE HEALTH INC FORMERLY | [ELV](https://holderbook.com/stocks/ELV/) | $1.5M | 5,000 | 1.1% | 2 |
| ENCOMPASS HEALTH CORP | [EHC](https://holderbook.com/stocks/EHC/) | $1.5M | 15,000 | 1.1% | 24 |
| CVS HEALTH CORP | [CVS](https://holderbook.com/stocks/CVS/) | $1.4M | 20,000 | 1.1% | 2 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +10.1% | +14.8% | -4.7% | 96% |
| Q1 2026 | -7.5% | -4.6% | -2.9% | 100% |
| Q4 2025 | +7.9% | +2.4% | +5.5% | 100% |
| Q3 2025 | +3.1% | +7.8% | -4.7% | 100% |
| Q2 2025 | +2.9% | +10.5% | -7.6% | 100% |
| Q1 2025 | +3.0% | -4.6% | +7.6% | 100% |
| Q4 2024 | -11.5% | +2.1% | -13.6% | 100% |
| Q3 2024 | +4.8% | +5.4% | -0.7% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $131.7M | 34 |
| Q1 2026 | $131.7M | 34 |
| Q4 2025 | $344.6M | 49 |
| Q3 2025 | $343.7M | 44 |
| Q2 2025 | $367.6M | 46 |
| Q1 2025 | $185.0M | 31 |
| Q4 2024 | $189.9M | 38 |
| Q3 2024 | $236.2M | 35 |
| Q2 2024 | $278.4M | 38 |
| Q1 2024 | $426.6M | 47 |
| Q4 2023 | $239.4M | 39 |
| Q3 2023 | $197.9M | 33 |